retatrutide parkinson clinical trial Parkinson's drug pipeline evolution and future directions | Michael S Okun posted on the topic Retatrutide for the treatment of

There are many ongoing treatment trials based on EBM findings

However, because GLP-1 receptor agonists slow gastric emptying and alter gastrointestinal motility, patients without a gallbladder may notice different digestive sensations compared to those with an intact biliary system

Pharmacother: J Human Pharmacol Drug Therapy

GLP1 potentiates insulin secretion and suppresses glucagon secretion, regulating overall glycaemic control

GLP-1s and SGLT2s: The New Power Players in Diabetes Care By 2024, more Medicare patients with T2D are sticking with GLP-1 or SGLT2 therapies as their sole treatment, doubling since 2020